Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05005728 · ClinicalTrials.gov registry record · Phase 2
XmAb®20717 (Vudalimab) Alone or in Combination With Chemotherapy or Targeted Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer
A Phase 2 study, sponsored by Xencor.
- Completed
- Registry status
- Phase 2
- Development phase
- 72
- Enrollment target
NCT05005728 is a Phase 2 study that has completed, run by Xencor. The registered enrollment target is 72 participants.
The verdict
NCT05005728, a Phase 2 study, has completed, sponsored by Xencor.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 72 participants
- Enrollment target
Study Summary
This Phase 2 study will investigate the safety and clinical activity of vudalimab (XmAb20717) alone or in combination with standard of care anticancer therapies in patients with metastatic castration-resistant prostate cancer (mCRPC) who have progressed on prior therapy.
Interventions
- COMBINATION_PRODUCT vudalimab + carboplatin + cabazitaxel
- COMBINATION_PRODUCT vudalimab + olaparib
- BIOLOGICAL vudalimab monotherapy
- COMBINATION_PRODUCT vudalimab + docetaxel
- COMBINATION_PRODUCT vudalimab + cabazitaxel or docetaxel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 72 participants |
| Start Date | 2021-10-22 |
| Est. Completion | 2025-06-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05005728
The ClinicalTrials.gov registry entry for NCT05005728 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 72 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Xencor, which has 27 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which vudalimab + carboplatin + cabazitaxel is the first listed.
NCT05005728 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05005728 about?
NCT05005728 is a clinical study titled "XmAb®20717 (Vudalimab) Alone or in Combination With Chemotherapy or Targeted Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer". This Phase 2 study will investigate the safety and clinical activity of vudalimab (XmAb20717) alone or in combination with standard of care anticancer therapies in patients with metastatic castration-resistant prostate cancer (mCRPC) who have progressed on prior therapy.
What is the current status of trial NCT05005728?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 72 participants. The study started on 2021-10-22. Estimated completion is 2025-06-10.
What interventions are being tested in trial NCT05005728?
The interventions under investigation include: vudalimab + carboplatin + cabazitaxel (COMBINATION_PRODUCT), vudalimab + olaparib (COMBINATION_PRODUCT), vudalimab monotherapy (BIOLOGICAL), vudalimab + docetaxel (COMBINATION_PRODUCT), vudalimab + cabazitaxel or docetaxel (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT05005728?
This trial is sponsored by Xencor, which has 27 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.